Trials / Conditions / Primary Immune Thrombocytopenia (ITP)

Primary Immune Thrombocytopenia (ITP)

22 registered clinical trials studyying Primary Immune Thrombocytopenia (ITP) — 13 currently recruiting.

Status	Trial	Sponsor	Phase
Not Yet Recruiting	A Study to Assess the Tolerability of Ianalumab (VAY736) With Investigator's Choice Thrombopoietin Receptor Ag NCT07421167	Novartis Pharmaceuticals	Phase 2
Not Yet Recruiting	Phase II Study of Orelabrutinib in Combination With Romiplostim N01 in Patients With Primary Immune Thrombocyt NCT07400250	Peking Union Medical College Hospital	Phase 2
Not Yet Recruiting	rhTPO Dose Escalation vs Eltrombopag Switch in ITP NCT07476846	Institute of Hematology & Blood Diseases Hospital, China	N/A
Not Yet Recruiting	Sequential rhTPO and Eltrombopag Following Glucocorticoids for Severe Adult ITP NCT07189910	Union Hospital, Tongji Medical College, Huazhong University of Science and Technology	Phase 4
Recruiting	An Open-label Study of Intravenous Immunoglobulin (5%) for the Treatment of Primary Immune Thrombocytopenia NCT07233213	Grand Shuyang Life Sciences (Chengdu) Co., Ltd.	Phase 3
Not Yet Recruiting	A PHASE II TRIAL AIMING TO INVESTIGATE THE SAFETY AND CLINICAL ACTIVITY OF BELANTAMAB MAFODOTIN IN ADULT PATIE NCT07019545	Hellenic Society of Hematology	Phase 2
Recruiting	Romiplostim N01 Combined With Glucocorticoids as the First-line Treatment for Newly Diagnosed Adult Primary Im NCT06992128	Institute of Hematology & Blood Diseases Hospital, China	Phase 2
Recruiting	A Phase Ib/II Clinical Trial of Multiple Doses of STSA-1301 Subcutaneous Injection in Healthy Subjects and Pat NCT06929299	Jiangsu BioJeTay Biotechnology Co., Ltd.	Phase 1 / Phase 2
Recruiting	Study of PN20 in Adult Patients With Primary Immune Thrombocytopenia (ITP) NCT06880081	Chongqing Peg-Bio Biopharm Co., Ltd.	Phase 1
Recruiting	Safety Study of CC312 in Autoimmune Disease Patients NCT06888960	CytoCares Inc	EARLY_Phase 1
Recruiting	A Study to Assess the Efficacy and Safety of Efgartigimod IV in Adult Participants With Primary Immune Thrombo NCT06544499	argenx	Phase 3
Recruiting	RESTI Registry: Spanish Registry of Primary Immune Thrombocytopenia and Other Immune Thrombocytopenia NCT06919341	Fundación Española de Hematología y Hemoterapía	—
Active Not Recruiting	A Study of Ianalumab (VAY736) in Patients With Primary Immune Thrombocytopenia (ITP) Previously Treated With a NCT05885555	Novartis Pharmaceuticals	Phase 2
Unknown	TPO-RAs Combining Anti-CD 20 Monoclonal Antibody Versus TPO-RAs in the Management of Pediatric Primary Immune NCT05718856	Institute of Hematology & Blood Diseases Hospital, China	Phase 4
Active Not Recruiting	Study of Ianalumab Versus Placebo in Addition to First-line Corticosteroids in Primary Immune Thrombocytopenia NCT05653349	Novartis Pharmaceuticals	Phase 3
Completed	Evaluation of the Use of Thrombopoietin Receptor Agonists in Adults With Primary ITP in Europe NCT06408324	European Research Consortium on ITP	—
Recruiting	Efficacy and Safety of Subcutaneous Belimumab or Placebo in Addition of Rituximab in Persistent or Chronic Imm NCT05338190	Assistance Publique - Hôpitaux de Paris	Phase 3
Completed	Immunomodulation With Eltrombopag in ITP NCT04812483	University Children's Hospital Basel	Phase 2
Active Not Recruiting	Phase III Study on HMPL-523 for Treatment of ITP NCT05029635	Hutchison Medipharma Limited	Phase 3
Unknown	Eltrombopag Combining Rituximab Versus Eltrombopag in the Management of Primary Immune Thrombocytopenia (ITP) NCT04518475	Institute of Hematology & Blood Diseases Hospital, China	Phase 4
Withdrawn	A Study to Assess the Efficacy and Safety of Efgartigimod in Adult Patients With Primary Immune Thrombocytopen NCT04274452	argenx	Phase 3
Completed	Study of Immune Thrombocytopenia Pathogenesis: NCT02042560	Centre Hospitalier Universitaire Dijon	—